USA - engelsk - NLM (National Library of Medicine)

andrx pharmaceuticals, inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tablet - 10 mg - metastatic breast cancer: tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. adjuvant treatment of breast cancer: tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with 4 or more positive axillary nodes. tamoxifen is indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen and progesterone receptor values may help to predict whet

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tamoxifen citrate, quantity: 30.34 mg (equivalent: tamoxifen, qty 20 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; brilliant scarlet 4r; povidone - treatment of breast cancer tamoxifen lupin is indicated for the treatment of breast cancer.,primary reduction of breast cancer risk tamoxifen lupin is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

USA - engelsk - NLM (National Library of Medicine)

aurobindo pharma limited - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - metastatic breast cancer: tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablets therapy. adjuvant treatment of breast cancer: tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen citrate adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen and progester

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg;   - tablet - 20 mg - active: tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg   excipient: croscarmellose sodium gelatin hypromellose lactose monohydrate macrogol 300 magnesium stearate maize starch titanium dioxide

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg;   - tablet - 20 mg - active: tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone purified talc

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg - tablet - 20 mg - active: tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose potato starch povidone sodium starch glycolate

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen 20 mg - tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. t

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; hypromellose; macrogol 4000; magnesium stearate; sodium starch glycollate - treatment of breast cancer. ? tamoxifen sandoz is indicated for the treatment of breast cancer.,primary reduction of breast cancer risk ? tamoxifen sandoz is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; croscarmellose sodium; maize starch; mannitol - treatment of breast cancer. genox is indicated for the treatment of breast cancer. primary reduction of breast cancer risk. genox is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

USA - engelsk - NLM (National Library of Medicine)

remedyrepack inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen citrate tablets, usp are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. tamoxifen citrate tablets, usp are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. tamoxifen citrate tablets, usp are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to b